An interventional study of OPM- Magnetoencephalography in Autoimmune Encephalitis (AE), Acute Disseminated Encephalomyelitis and Multiple Sclerosis, sponsored by Aston University. Recruiting at 2 sites in United Kingdom. Open to participants aged 2 Years to 16 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-22.
Sponsored by Aston University · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 252 studies in Multiple Sclerosis with a site in United Kingdom — 28 open to participants now, 46 under way, 11 of them phase 3. Multiple Sclerosis · United Kingdom.
Among the 252 studies in Multiple Sclerosis with a site in United Kingdom, this one is the 111th largest by planned enrollment of the 195 interventional ones that give a count, is one of 5 that started in 2026, is one of 43 with no phase, reaches primary completion later than 45 of the 45 other live ones, and was the 250th registered.
3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →28 of the 252 studies in Multiple Sclerosis with a site in United Kingdom are open now. Recruiting first, the newest first:
Imperial College London · Sites in United Kingdom
Ages 18+
Swansea University · Sites in United Kingdom
Ages 18+
AstraZeneca · Sites in United Kingdom, United States, Australia and 2 more countries
Ages 18–60
Oxford University Hospitals NHS Trust · Sites in United Kingdom
Ages 18+
Novartis Pharmaceuticals · Sites in United Kingdom, United States, Argentina and 33 more countries
Ages 18–65
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.
This study: 2 Years to 16 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
252 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 47 · Phase 3 72 · Phase 4 15
First in 1999; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 90 is above the median of 50 across 2,208 interventional studies indexed under Multiple Sclerosis.
Median enrollment 136 across the 195 interventional studies, 200 across the 57 observational. Of the 187 that completed or were terminated, 95 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
154 of 252 have an industry lead sponsor. The 10 most frequent:
Aston University is the lead sponsor of 27 studies on the registry; 8 are open to participants now.
Aston University has 1 study filed under Multiple Sclerosis — fewer than ten, so there is no comparison to draw.
11 of the studies in Multiple Sclerosis with a site in United Kingdom that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06141473Phase 3SanofiEfficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis | 2027-05-06 |
| NCT06274671University of ExeterGlymphatic MRI in Clinically Isolated Syndrome | 2026-12-31 |
| NCT07452562Swansea UniversityHesperidin RCT in MS | 2027-01-18 |
| NCT07111637Queen Mary University of LondonArtificial Intelligence-Assisted Magnetic Resonance Imaging for Quality, Efficiency and Equity in the National Health Service (NHS) Care of Multiple Sclerosis | 2027-04-14 |
| NCT06900244University of OxfordMetabolic Imaging of Neurological Disease | 2027-06 |
Add all 11 to your calendar (.ics) → With an account.
Among the 252 studies in Multiple Sclerosis with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Over the past 20 years, doctors have gotten much better at spotting and treating brain conditions caused by the immune system attacking the body. These include illnesses like autoimmune encephalitis, ADEM, and multiple sclerosis. But even with better treatments, many patients-especially children-still struggle with long-term problems. Standard brain scans and tests often miss important issues like memory problems, emotional difficulties, trouble sleeping, and challenges with social behaviour. Early research using a special brain imaging technique (called MEG) has shown changes in brain networks that seem to be linked to poor memory. This study will use a new, advanced version of MEG that works even with very young children (as young as 2 years old). The goal is to better understand how these brain conditions affect children, compare them with other types of brain illness, and eventually use this technology to help predict outcomes and discover new ways to track brain health.
This study is an 8-year cross-sectional and observational cohort study involving the use of OPM-MEG, MEG, MRI and neuropsychology testing based at the Aston Institute of Health and Neurodevelopment, Birmingham, UK. Children and young people with immune and non-immune mediated neurological disease aged 2-15 years will be recruited locally (Birmingham Children's Hospital) and from London and Manchester.
The longitudinal cohorts (n=25 in each, total n=50) will be those with immune- and non-immune mediated neurological disease within 9 months of diagnosis. They will be invited for 3 study visits (Study Visits 1, 2 and 3).
The cross-sectional cohort (n=25) will be those with immune-mediated neurological disease at least 18 months after diagnosis. They will be invited to for one study visit (Study Visit 1).
The study visits:
At Study Visit 1 (Baseline), participants will undergo OPM-MEG, MEG and MRI as well as neuropsychology testing and questionnaire completion. Total time taken is 5 hours. This visit can be split into 2 visits within a 2 week window.
At Study Visit 2 (2 years)and 3 (5 years) participants will undergo OPM-MEG, MEG and MRI and questionnaire completion. Total time taken is 3 hours.
Participants travelling from outside the West Midlands will be offered overnight accommodation for Study Visits.
The participants are welcome to have as many breaks as is necessary during each/any Study Visit. It is expected that breaks will last between 15 minutes to one hour. Refreshments will be available for the participants on the day and will ask in advance of the visit in case of any allergies. Aston University, where the IHN is based, has food outlets Tesco, Greggs and Costa Coffee available too. Another adult, aside from the research team, can be present during the research recordings.
3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
This study's planned enrollment of 90 is above the median of 50 across 2,208 interventional studies indexed under Multiple Sclerosis.
Browse Multiple Sclerosis studies →Aston University is the lead sponsor of 27 studies on the registry; 8 are open to participants now.
Compared within Multiple Sclerosis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Autoimmune Diseases of the Nervous System. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Longitudinal - participants who are within 9 months of disease
Device: OPM- Magnetoencephalography
To assess the changes in brain network function that occur in relation to immune and non-immune mediated brain disease, participants will undergo OPM-MEG recording. This will be conducted at all study visits. To assess the behavioural and functional changes following disease from the patient and caregiver perspective questionnaires will be completed on paper-based forms. These are all established outcomes measures used in our and others' previous studies in immune and non-immune mediated disease in children. The cryogenic MEG recording will also assess changes in brain dysfunction and will be directly comparable to the advanced OPM-MEG data. To assess the effect of disease on brain structures, participants will undergo MRI scanning at the IHN. To assess functional outcomes of immune and non-immune mediated disease, participants will undergo neuropsychology assessments.
Also known as: MRI, neuropsychology assessment
Detection of group differences over time in imaging metrics using OPM-MEG.
Change from Baseline in OPM-MEG Resting-State Delta-Band (1-4 Hz) Local Efficiency Local efficiency of resting-state brain networks derived from OPM-MEG recordings, computed from amplitude envelope correlation connectivity matrices (Desikan-Killiany atlas parcellation) using the Brain Connectivity Toolbox, compared between participants with immune-mediated and non-immune-mediated neurological disease across proportional connectivity thresholds (10-30%).
Time frame: Baseline (Study Visit 1), 2 years (Study Visit 2), 5 years (Study Visit 3)
Change from Baseline in Whole-Brain Cortical Thickness
Mean cortical thickness across the whole brain, measured from T1-weighted MRI using FreeSurfer surface-based analysis, compared between disease groups.
Time frame: Baseline, 2 years, 5 years
Correlation Between Resting-State Network Graph Measures and Wechsler Working Memory Index Score
Association between OPM-MEG/MEG-derived delta and theta local efficiency, global efficiency, and modularity values (particularly theta modularity) and Working Memory Index composite scores from the Wechsler Intelligence Scale for Children - Fifth Edition and the Wechsler Preschool and Primary Scale of Intelligence - Fourth Edition (WISC-V/WPPSI-4), analyzed by multiple regression controlling for sex. On the WISC-V and WPPSI-IV, the theoretical minimum Full Scale IQ score is 40 and the maximum score is 160, with higher scores indicating better cognitive outcomes and stronger academic potential.
Time frame: Baseline, 2 years, 5 years
Diagnostic/Predictive Performance of Imaging Metrics for Clinical Outcome Group (mRS-Defined)
Sensitivity/specificity or area-under-curve of OPM-MEG, MEG, and MRI-derived metrics (local efficiency, modularity, cortical thickness) for classifying participants by modified Rankin Scale outcome category at follow-up.
Time frame: 2 years, 5 years
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Data from this cohort may be highly valuable to future research efforts. Thus, we will ask participants to provide written informed consent to make their anonymised data freely available for reanalysis by the team in future studies, and to researchers outside of the study team for use in ethically approved projects. Specifically, neuroimaging (MRI), questionnaire, neuropsychology (summary scores) and demographic data that are suitable for sharing will be made available, using open-access data repositories platforms such as OSF (osf.org) or other suitable platforms which meet current best practice within the field, in relation to local and national regulations (i.e. GDPR). Open-access sharing of data will only happen once the linking document (linking study ID to personal identifiable data i.e. name) is destroyed (3 years after study end), to ensure that shared data is truly anonymous, not pseudo-anonymised
Supporting information: Study protocol
Time frame: 3 years after study end after linking document destroyed September 2037 to September 2047
Access criteria: Only the PI and study team
Data sharing details ↗ · www.aston.ac.uk
Started May 2026 (actual). Primary completion is estimated for Sep 2034, 100 months after the start.
Of 852 non-industry interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's planned 100 months is above that.
Counting every sponsor, half of 874 studies reached it within 21 months; a quarter within 9 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Aston University